12.21.22
Aton Biotech, a CDMO committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform, and KangaBio have announced a strategic collaboration.
Both parties aim to share resources and achieve joint development on the principle of equality and mutual benefits. Aton Biotech will provide CDMO services for the innovative drugs of KangaBio, which includes cell line development, cell bank construction and verification, process development and optimization, analytical method development, process transfer and confirmation, clinical manufacturing, commercial scale manufacturing, stability study and IND & NDA filing support, etc.
“KangaBio is a biotech company focused on providing innovative medicine to address unmet medical needs. We are working on developing prodrugs of immune-stimulating agents and other multi-specific biologics to avoid toxicities for previously validated targets and to increase drug efficacy,” said Dr. Weidong Jiang, founder and CEO of KangaBio. “It is a great pleasure to reach this strategic cooperation with Aton Biotech. Aton Biotech has industry-leading antibody drug development, clinical production and commercial production experience and platform advantages, and has established a quality system that meets international GMP requirements. It is hoped that based on the existing projects, the cooperation between the two parties will continue to deepen, so as to benefit patients as soon as possible with better innovative drugs.”
“Aton Biotech is very pleased to provide CDMO services for KangaBio, and we are very grateful for the trust from KangaBio,” said Ms. Wei Huang, COO and SVP of Henlius and chairman of Aton Biotech. “Aton Biotech is committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform and has accumulated rich experience in many areas such as process development, manufacturing and regulatory. Aton Biotech will continue to uphold the concept of ‘quality, integrity, efficient, excellence,’ and look forward to more in-depth cooperation between the two parties in the future to accelerate KangaBio’s molecule to market and benefit more patients.”
Both parties aim to share resources and achieve joint development on the principle of equality and mutual benefits. Aton Biotech will provide CDMO services for the innovative drugs of KangaBio, which includes cell line development, cell bank construction and verification, process development and optimization, analytical method development, process transfer and confirmation, clinical manufacturing, commercial scale manufacturing, stability study and IND & NDA filing support, etc.
“KangaBio is a biotech company focused on providing innovative medicine to address unmet medical needs. We are working on developing prodrugs of immune-stimulating agents and other multi-specific biologics to avoid toxicities for previously validated targets and to increase drug efficacy,” said Dr. Weidong Jiang, founder and CEO of KangaBio. “It is a great pleasure to reach this strategic cooperation with Aton Biotech. Aton Biotech has industry-leading antibody drug development, clinical production and commercial production experience and platform advantages, and has established a quality system that meets international GMP requirements. It is hoped that based on the existing projects, the cooperation between the two parties will continue to deepen, so as to benefit patients as soon as possible with better innovative drugs.”
“Aton Biotech is very pleased to provide CDMO services for KangaBio, and we are very grateful for the trust from KangaBio,” said Ms. Wei Huang, COO and SVP of Henlius and chairman of Aton Biotech. “Aton Biotech is committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform and has accumulated rich experience in many areas such as process development, manufacturing and regulatory. Aton Biotech will continue to uphold the concept of ‘quality, integrity, efficient, excellence,’ and look forward to more in-depth cooperation between the two parties in the future to accelerate KangaBio’s molecule to market and benefit more patients.”
